Table 5 Levels of evidence for favourable-histology Wilms tumour risk-stratification features
Level of evidence117 | Feature | Part of updated COG risk stratification? |
---|---|---|
I | Stage | Yes |
Histology | Yes | |
LOH of 1p and 16q | Yes | |
Lung metastatic response to chemotherapy | Yes | |
II | Lymph node sampling | Yes |
Age | Yes | |
Tumour nephrectomy weight | No | |
Extra pulmonary metastasisa | Yes | |
11p15 status in patients with very-low-risk disease | Yes | |
Epithelial-predominant histology | Yes | |
1q gain | Yes | |
Lymph node involvement with isolated LOH 1p/16q | Yes | |
Post-chemotherapy blastemal-predominant histology | Yes | |
Peritoneal metastases | Yesb | |
Partial nephrectomy for unilateral Wilms tumour | No | |
Unilateral multifocal tumours | No | |
III | Tumour involving adrenal gland | Nob |
Inferior vena cava thrombus | Nob | |
IV | Extrarenal Wilms tumour | No |
V | Malignant pleural effusions | Yesb |
Tumour pulmonary emboli | Yesb | |
Extra-abdominal lymph nodes not pathologically sampled | Nob | |
Malignant ascites (peritoneal fluid) | No | |
Contralateral nephrogenic rests | No | |
Tumour in renal collecting system | Nob | |
Genetic predisposition to Wilms tumour | Yesc |